| Description | Potent, noncompetitive human CCR2 antagonist; inhibits MCP-1-induced Ca2+ mobilization in hCCR2-CHO cells (IC50 = 13 nM). Exhibits selectivity for CCR2 over CCR1, CCR3-8 and CXCR1-3. Delays onset and reduces neurological signs in an experimental autoimmune encephalomyelitis model of multiple sclerosis in hCCR2 knock-in mice. Orally active. Purity 98%. MW (observed): 379.38 |
|---|